Hasil Pencarian - Douglas Arbetter

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

    Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial oleh F. D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Douglas Arbetter, Seth Seegobin, Alexandre Kiazand, Katie Streicher, Nuria Martinez-Alier, Taylor S. Cohen, Mark T. Esser

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy

    Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy oleh C. Michael Gibson, Serge Korjian, Gerald Chi, Yazan Daaboul, Purva Jain, Douglas Arbetter, Samuel Z. Goldhaber, Russel Hull, Adrian F. Hernandez, Renato D. Lopes, Alex Gold, Alexander T. Cohen, Robert A. Harrington

    Diterbitkan 2017-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

    Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial) oleh Gustavo H. Kijak, Bahar Ahani, Douglas Arbetter, Fernando Chuecos, Vancheswaran Gopalakrishnan, Jagadish Beloor, Tyler Brady, Amy Nguyen, Tiffany L. Roe, Nicolette Schuko, Tianhui Zhang, F. D. Richard Hobbs, Francisco Padilla, Elizabeth J. Kelly, Hugh Montgomery, Katie Streicher

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

    Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial oleh F. D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Kenneth Kim, Douglas Arbetter, Kelly W. Padilla, Venkatesh Pilla Reddy, Seth Seegobin, Katie Streicher, Alison Templeton, Rolando M. Viani, Eva Johnsson, Gavin C. K. W. Koh, Mark T. Esser

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: